Business Context and Reporting Period
Company: Madrigal Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2023
Event: Entry into a First Amendment to the Loan and Security Agreement dated May 9, 2022, with Hercules Capital, Inc. and other lenders.
Key Financial Metrics and Debt Structure
- Total Committed Facility: $250.0 million in term loans.
- Outstanding Borrowings: $85.0 million as of February 3, 2023 ($50.0 million from Tranche 1 and $35.0 million drawn from Tranche 2).
- Interest Rate: Variable rate based on the greater of (i) Prime Rate + 2.45% or (ii) 8.25%. The amendment reduced borrowing costs by 150 basis points to 10.2% as of the filing date.
- Maturity Date: Scheduled for May 1, 2026, with potential extensions to May 1, 2027, contingent on FDA approval and revenue milestones.
- Repayment Terms: Interest-only period extended through May 1, 2025, following the achievement of a Phase 3 clinical development milestone.
Material Changes Versus Prior Period
- Interest Rate Reduction: Adjusted the interest rate formula, resulting in an immediate 150 basis point reduction in borrowing costs.
- Tranche 2 Expansion: Increased the committed amount for Tranche 2 by $15.0 million to $65.0 million. The company drew $35.0 million immediately and retains capacity to draw an additional $30.0 million by September 30, 2023.
- Tranche 4 Reduction: Reduced the committed amount for Tranche 4 by $15.0 million to $60.0 million to offset the Tranche 2 expansion.
- Warrant Restructuring: Terminated rights to previously unvested warrants (59,545 shares at $67.12/share). Issued new Tranche 2 warrants for 2,543 shares at an exercise price of $285.31 per share.
Outlook, Risks, and Management Commentary
- Clinical Milestone Achievement: The company confirmed satisfaction of the Phase 3 clinical development milestone under Tranche 2, triggering the interest-only extension and the ability to draw additional funds.
- Future Funding Conditions: Tranche 3 ($75.0 million) remains available subject to FDA approval for resmetirom. Tranche 4 ($60.0 million) is subject to the sole discretion of Hercules Capital, Inc.
- Equity Dilution Risk: Future borrowings under Tranches 2, 3, and 4 will require the issuance of warrants equal to 2.0% of the principal amount funded, with exercise prices tied to stock volume-weighted averages or fixed rates.
- Liquidity: The amendment enhances liquidity by providing access to additional committed capital ($30.0 million) over the next 18 months while lowering the cost of existing debt.
Investor Verification Checklist
- Verify the current Prime Rate to calculate the exact effective interest rate (Prime + 2.45% vs. 8.25% floor).
- Confirm the status of the resmetirom FDA approval, which is the trigger for accessing the $75.0 million Tranche 3.
- Review the specific financial covenants required to maintain the extended interest-only period and maturity date extensions.
- Monitor the volume-weighted average price of MDGL stock to determine the exercise price for future Tranche 3 and 4 warrants.
- Check for any subsequent draws on the $30.0 million remaining Tranche 2 capacity by June 19, 2023, and September 30, 2023.